CoChat

Troglitazone and liver injury: In search of answers†

Chojkier, Mario · 2005 · Hepatology
Cited by 125

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Troglitazone (TGZ) (Rezulin; Pfizer, Madison, NJ) was withdrawn from the market by the U.S. Food and Drug Administration (FDA) in March 2000, because it was associated with the development of acute liver failure.1 Approximately 35,000 TGZ injury claims are pending within the United States.2 However, even 4 years later, the mechanisms of TGZ-induced liver injury remain highly controversial and poorly understood. A review of the topic proposed that TGZ hepatotoxicity was mediated through the induction of steatosis and apoptosis and that the injury could be silent (without increased serum aminotransferases, bilirubin, or alkaline phosphatase).3 In addition, it has been suggested that TGZ may induce liver injury as a consequence of mitochondrial damage, oxidative stress, or by inhibiting the bile salt excretory protein (Bsep).3 Furthermore, these effects have been attributed, at least in part, to the accumulation of TGZ in the liver, particularly among patients with liver disease, as well as to the peculiar metabolism of the drug.3 Finally, it has been postulated that liver fibrosis and cancer may result from TGZ hepatotoxicity.3 These presumed chronic complications would constitute an extraordinary medical burden to the approximately 1.92 million patients treated with TGZ. Because these alleged long-term complications of TGZ-induced liver injury have significant medical, social, legal, and financial repercussions, this review evaluates the scientific merits of the proposed mechanisms and suggest alternative explanations. TGZ, troglitazone; FDA, Food and Drug Administration; Bsep, bile salt excretory protein; PPAR, peroxisomal proliferator-activated receptor; ALT, alanine aminotransferase; NASH, nonalcoholic steatohepatitis; Cmax, maximal concentration; TNF, tumor necrosis factor. Insulin resistance can result from an inherited defect in mitochondrial oxidative phosphorylation in children of patients with type 2 diabetes4 or from acquired defects in mitochondrial biogenesis,5 which leads to reductions in mitochondrial function, in elderly individuals.6 TGZ, a peroxisomal proliferator-activated receptor (PPAR)-γ agonist that improved insulin resistance, was used for the treatment of type 2 diabetes7, 8 in the United States by approximately 1.92 million patients from March 1997 to March 2000.9 As a consequence of the improved insulin sensitivity,8 TGZ had beneficial cardiovascular effects,10-13 protected pancreatic β-cell function,14 and corrected metabolic abnormalities associated with polycystic ovarian syndrome15 and lipodystrophy.16 In addition, TGZ antagonized the corticosteroid induction of insulin resistance and abnormal glucose tolerance.17 In clinical trials, 1.9% of the subjects who received TGZ and 0.6% of the subjects who received placebo had elevations (≥3 times the upper limit of normal) of serum alanine aminotransferase (ALT) concentrations.18 In this cohort of 2,510 subjects, TGZ induced overt liver injury and jaundice in two individuals.18 A retrospective analysis also concluded that approximately 2% of the patients developed TGZ-induced liver injury judging by the serum ALT elevations.19 By comparison, serum ALT elevations (≥3 times the upper limit of normal) occurred in approximately 25% of subjects taking tacrine,20 a drug that has not been associated with acute liver failure; however, probably fewer than 100,000 patients have been treated with this drug. Unfortunately, 94 of the 1.92 million patients developed liver failure while taking TGZ.1 Although only 49 of these liver failure cases were considered to be possibly or probably related to TGZ,9 the numbers may be higher because of incompleteness of reporting.1 TGZ treatment was associated with a characteristic hepatocellular injury,18, 21-35 with rare instances of either a mixed hepatocellular/cholestatic injury or a predominant cholestatic reaction.36-38 The liver injury associated with TGZ is idiosyncratic39; it is unpredictable, neither time- nor dose-dependent,40 and cannot be reproduced in animals.41-43 Although the mechanism of liver injury induced by TGZ is believed to be a metabolic idiosyncrasy (nonimmunological),39 some of the case reports had histological evidences suggestive of an immunological reaction16, 25, 27, 36 or responded favorably to corticosteroids.28, 38 One of these patients promptly developed a similar destructive, granulomatous cholangitis when treated subsequently with rosiglitazone, a related PPAR-γ agonist,38 supporting the diagnosis of an immunological reaction and suggesting a class effect. According to Zimmerman and Ishak44 and Klatskin and Conn,45 the occurrence of numerous eosinophils or granulomatous inflammatory infiltrates in the liver is sufficiently compelling, albeit circumstantial, evidence that hypersensitivity may play an important role in the injury provoked by TGZ in some patients. Although valuable to the medical and scientific community, neither the MedWatch Reports to the FDA nor the published

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.20567

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

Metadata

Authors
Chojkier, M.
Venue
Hepatology
Published
2005-02
Volume
41
Issue
2
Pages
237-246
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1981438405
Cited by
125
References
29
FWCI
8.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.